Novo Nordisk will soon resubmit Tresiba to the FDA, earlier than once expected. The escalated timeline provided a substantial boost to Novo's shares, but the news adds pressure to Sanofi's new CEO since Tresiba targets Lantus, the French drugmaker's top seller.
After a surprise FDA rejection sent it back to the drawing board in 2013, Novo Nordisk is finally ready to resubmit Tresiba, a long-acting insulin with blockbuster potential.
Novo Nordisk, in the process of exiting autoimmune R&D, has found a new home for one of its early-stage programs, handing it over to Bristol-Myers Squibb for an undisclosed sum.
Novo Nordisk, not long for the world of autoimmune R&D, has found a new home for one of its early-stage programs, handing it over to Bristol-Myers Squibb for an undisclosed sum.
Chalk up another success for a drugmaker setting one of its units free. Novo Nordisk's newly public IT business got off to a flying start Friday, its first day on the Copenhagen stock market, with shares rising by as much as 44%, Reuters reports.
Novo Nordisk has set the terms for the IPO of its IT services unit NNIT. If NNIT prices at the top end of its range when it goes public in the next week or so, the listing could generate up to $335 million for Novo Nordisk.
Here is part two of comments from C-suite execs on emerging markets and Asia in the latest quarterly conference calls.
Novo Nordisk's new oral diabetes drug measured up to its injected counterpart in a midstage study, promising results the company heralds as a milestone in the field.
Merck and Novo Nordisk are the latest pharma recruits for the GPCR Consortium, a global nonprofit working to shed light on an underexplored corner of biology and share its discoveries with the public.
Novo Nordisk has decided to go ahead with the long-discussed IPO of its IT services unit NNIT. The Danish drugmaker spent the past year weighing up the merits of a public listing, which analysts have speculated could value the company at anywhere from $460 million to $1.2 billion.